001     143493
005     20240229123016.0
024 7 _ |a 10.1002/ijc.32233
|2 doi
024 7 _ |a pmid:30807653
|2 pmid
024 7 _ |a 0020-7136
|2 ISSN
024 7 _ |a 1097-0215
|2 ISSN
024 7 _ |a altmetric:56223218
|2 altmetric
037 _ _ |a DKFZ-2019-01080
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Perez-Cornago, Aurora
|0 0000-0002-5652-356X
|b 0
245 _ _ |a Intake of individual fatty acids and risk of prostate cancer in the European prospective investigation into cancer and nutrition.
260 _ _ |a Bognor Regis
|c 2020
|b Wiley-Liss
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1574070049_29288
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a 146(1):44-57
520 _ _ |a The associations of individual dietary fatty acids with prostate cancer risk have not been examined comprehensively. We examined the prospective association of individual dietary fatty acids with prostate cancer risk overall, by tumor subtypes, and prostate cancer death. 142,239 men from the European Prospective Investigation into Cancer and Nutrition who were free from cancer at recruitment were included. Dietary intakes of individual fatty acids were estimated using center-specific validated dietary questionnaires at baseline and calibrated with 24-h recalls. Multivariable Cox regression models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs). After an average follow-up of 13.9 years, 7,036 prostate cancer cases and 936 prostate cancer deaths were ascertained. Intakes of individual fatty acids were not related to overall prostate cancer risk. There was evidence of heterogeneity in the association of some short chain saturated fatty acids with prostate cancer risk by tumor stage (pheterogeneity < 0.015), with a positive association with risk of advanced stage disease for butyric acid (4:0; HR1SD = 1.08; 95%CI = 1.01-1.15; p-trend = 0.026). There were no associations with fatal prostate cancer, with the exception of a slightly higher risk for those who consumed more eicosenoic acid (22:1n-9c; HR1SD = 1.05; 1.00-1.11; p-trend = 0.048) and eicosapentaenoic acid (20:5n-3c; HR1SD = 1.07; 1.00-1.14; p-trend = 0.045). There was no evidence that dietary intakes of individual fatty acids were associated with overall prostate cancer risk. However, a higher intake of butyric acid might be associated with a higher risk of advanced, whereas intakes of eicosenoic and eicosapentaenoic acids might be positively associated with fatal prostate cancer risk.
536 _ _ |a 313 - Cancer risk factors and prevention (POF3-313)
|0 G:(DE-HGF)POF3-313
|c POF3-313
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Huybrechts, Inge
|b 1
700 1 _ |a Appleby, Paul N
|b 2
700 1 _ |a Schmidt, Julie A
|0 0000-0002-7733-8750
|b 3
700 1 _ |a Crowe, Francesca L
|b 4
700 1 _ |a Overvad, Kim
|b 5
700 1 _ |a Tjønneland, Anne
|b 6
700 1 _ |a Kühn, Tilman
|0 P:(DE-He78)0907a10ba1dc8f53f04907f54f6fdcfe
|b 7
|u dkfz
700 1 _ |a Katzke, Verena
|0 P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4
|b 8
|u dkfz
700 1 _ |a Trichopoulou, Antonia
|b 9
700 1 _ |a Karakatsani, Anna
|b 10
700 1 _ |a Peppa, Eleni
|b 11
700 1 _ |a Grioni, Sara
|b 12
700 1 _ |a Palli, Domenico
|b 13
700 1 _ |a Sacerdote, Carlotta
|0 0000-0002-8008-5096
|b 14
700 1 _ |a Tumino, Rosario
|b 15
700 1 _ |a Bueno-de-Mesquita, H Bas
|b 16
700 1 _ |a Larrañaga, Nerea
|b 17
700 1 _ |a Sánchez, Maria-Jose
|b 18
700 1 _ |a Quirós, J Ramón
|b 19
700 1 _ |a Ardanaz, Eva
|b 20
700 1 _ |a Chirlaque, María-Dolores
|b 21
700 1 _ |a Agudo, Antonio
|b 22
700 1 _ |a Bjartell, Anders
|b 23
700 1 _ |a Wallström, Peter
|b 24
700 1 _ |a Chajes, Veronique
|0 0000-0003-1297-3064
|b 25
700 1 _ |a Tsilidis, Konstantinos K
|0 0000-0002-8452-8472
|b 26
700 1 _ |a Aune, Dagfinn
|b 27
700 1 _ |a Riboli, Elio
|b 28
700 1 _ |a Travis, Ruth C
|b 29
700 1 _ |a Key, Timothy J
|b 30
773 _ _ |a 10.1002/ijc.32233
|g p. ijc.32233
|0 PERI:(DE-600)1474822-8
|n 1
|p 44-57
|t International journal of cancer
|v 146
|y 2020
|x 1097-0215
909 C O |o oai:inrepo02.dkfz.de:143493
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 7
|6 P:(DE-He78)0907a10ba1dc8f53f04907f54f6fdcfe
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 8
|6 P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-313
|2 G:(DE-HGF)POF3-300
|v Cancer risk factors and prevention
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2020
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b INT J CANCER : 2017
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b INT J CANCER : 2017
920 1 _ |0 I:(DE-He78)C020-20160331
|k C020
|l Epidemiologie von Krebserkrankungen
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C020-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21